Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Biomind Labs Inc N.BMND

Alternate Symbol(s):  BMNDF

Healthcare
Biomind Labs Inc. is a biotech research and development company. It is focused on transforming biomedical sciences knowledge into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. Through its acceleration platform, Biomind Labs is developing novel pharmaceutical formulations of key endogenous substances which are occurring in the human body and an organic compound that includes many neurotransmitters for treating a range of therapeutic indications. DMT is a serotonergic psychedelic that exerts its effects through serotonergic receptors in the brain, including 5-HT2A, 5-HT1A, 5-HT2C and 5-HT7 receptors. 5-MeO-DMT is a powerful psychedelic tryptamine. Under the 5-MeO-DMT Program, it is focused on two drug candidates: BMND05: 5-MeO-DMT novel formulation indicated for Chronic Pain and BMND08: 5-MeO-DMT novel formulation indicated for Alzheimer’s disease. Mescaline is a psychedelic alkaloid of the phenethylamine class.


NEO:BMND - Post by User

Biomind Labs Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by adamsmon Dec 27, 2000 3:36pm
801 Views
Post# 3040822

Ouch, I just sold

Ouch, I just soldI hate to admit it but I just sold mine at 11.20, I figured I better take the money and run. I had high hopes for this stock but they never panned out. A bid at $10, what an insult. I hope to buy more once this frenzy is over. Good luck all the longs.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities